Janssen had better Darzalex sales than expected in Q1

Outside the US, Darzalex sales are going so well that they are close to overtaking US sales for Q1. In total, sales amounted to USD 1.37, from which Genmab receives royalties.

Photo: Joost Melis / Genmab / PR

US pharmaceutical company Jansssen holds the rights for Darzalex, which was developed by Danish biotech firm Genmab and has had significantly better sales than expected in this year's first quarter.

While analysts had forecast that Darzalex would sell for around USD 1.25bn, Janssen has fetched USD 1.37bn from this cancer drug, which is around 46 percent more than the same quarter in 2020.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs